As a world-leading service provider for antibody functional assessment, Creative Biolabs has successfully established a state-of-the-art antibody function analysis platform for exploiting more efficient antibody-based therapeutics. Targeting the immune checkpoints has attracted much attention for immunotherapy development. As with the co-inhibitory pathways, co-stimulatory pathways provide therapeutic targets for immunotherapy. CD40 is a co-stimulatory pathway molecule that has shown success when targeted with agonistic antibodies in both monotherapy and combination regimens. Now, we are happy to introduce our CD40 Bioassay for investigating the efficacy and stability of anti-CD40 antibodies.
CD40, which belongs to the tumor necrosis factor receptor (TNFR) family, is a 48 kDa type I transmembrane protein. CD40 is constitutively expressed on antigen-presenting cells (APCs) such as B cells and dendritic cells (DCs). Its ligand (CD40L), also known as CD154, is normally expressed by a number of activated cells, including T cells, B cells, and NK cells. The interaction between CD40 and CD154 has been found to regulate both humoral and cellular immune responses. The interaction between CD40 on DCs and CD154 on T cells leads to T cell activation. Moreover, CD40 can lead to the activation of B cells and macrophages, thereby activating neutrophils and NK cells. As a result, modulating the CD40-CD154 interaction has become a promising strategy for immune-related disease treatment. The blockade of CD40/CD40L has been reported to effectively stop the process of tumor progression in a mouse model and can prevent the induction of a series of autoimmune diseases, including arthritis and systemic lupus erythematosus. Promising antibodies targeting this interaction has been developed, such as Dacetuzumab (an anti-CD40 agonistic mAb) and Lucatumumab (100% humanized anti-CD40 antagonistic mAb).
Fig. 1 The interaction between CD40L and other components in tumor microenviroment.1
At Creative Biolabs, we can provide a panel of immune checkpoint interaction analysis services, which has been widely used for evaluating the potency and stability of antibodies targeting a range of immune checkpoints, such as CD40. Here, the CD40 Bioassay is a bioluminescent cell-based assay that overcomes the limitations of current methods (such as complex assay protocols, unqualified assay reagents, and dependent on donor primary cells). This assay can provide fast, accurate, and reliable results for your anti-CD40 antibody interaction analysis. We can also offer primary cell assays based on your specific requirements.
Creative Biolabs is a global CRO company committed to assisting global customers in therapeutic antibody discovery and functional analysis. Besides CD40, we also provide immune checkpoint reporter gene assays targeting other co-inhibitory and co-stimulatory molecules that have shown promise as therapeutic targets. If you are interested in our services, please feel free to contact us or send us an inquiry.
Reference
For Research Use Only.
